{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:48:54Z","timestamp":1787014134832,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001866"],"award-info":[{"award-number":["UL1 TR001866"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004343","name":"Stavros Niarchos Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The GALLIUM trial showed improved progression\u2010free survival (PFS) with obinutuzumab (O)\u2010based chemoimmunotherapy in first\u2010line treatment of follicular lymphoma (FL), although with increased toxicity compared to rituximab (R). Our previous real\u2010world study found similar toxicity between these protocols during induction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To compare real\u2010world toxicity and outcomes of R versus O maintenance therapy in FL patients following first\u2010line chemoimmunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter retrospective study included FL patients treated with first\u2010line R\u2010 or O\u2010based chemoimmunotherapy. The primary outcome was any infection up to 6\u2009months post\u2010maintenance. Secondary outcomes included other toxicities, PFS, and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We analyzed 134 patients (R: 71, O: 63). Baseline characteristics were similar except for higher diabetes and hypertension rates in the R group. The median number of maintenance cycles was comparable. Infections occurred in 56% of patients, with no significant difference (50.7% R vs. 61.9% O,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.21). Grade\u2009\u20093 infections, febrile neutropenia, and treatment discontinuation rates were comparable between groups. Pneumonia and viral infections were less frequent with R versus O (13.8% vs. 28.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019 and 19% vs. 39%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004, respectively), while infusion reactions were higher (8.4% vs. 0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028). After 5.5\u2009years, PFS favored O (19.7% vs. 4.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028), with similar OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real\u2010world settings, rituximab\u2010 and obinutuzumab\u2010based chemoimmunotherapy with maintenance for FL exhibited a similar toxicity profile, with differences in specific infections. Obinutuzumab had superior PFS and similar OS compared with rituximab therapy, supporting obinutuzumab usage in first\u2010line chemoimmunotherapy, especially in selected young and fit patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70136","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:45:46Z","timestamp":1770684346000},"page":"816-825","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable Toxicity"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0239-9265","authenticated-orcid":false,"given":"Renana","family":"Robinson","sequence":"first","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah\u2010Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Berger","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah\u2010Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Laboratory of Genome Maintenance The Rockefeller University  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzippy","family":"Shochat","sequence":"additional","affiliation":[{"name":"Bio\u2010Statistical Unit Rabin Medical Center, Beilinson Campus  Petah Tikva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomzion","family":"Aumann","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center and Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Nachmias","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center and Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center and Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurit","family":"Horesh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Rambam Health Care Campus  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4392-8485","authenticated-orcid":false,"given":"Reut","family":"Harel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Technion\u2010 Israel Institute of Technology  Haifa Israel"},{"name":"Hematology Unit, HaEmek Medical Center  Afula Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Aviv","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Technion\u2010 Israel Institute of Technology  Haifa Israel"},{"name":"Hematology Unit, HaEmek Medical Center  Afula Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idan","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah\u2010Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Shmerts","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2023-2848","authenticated-orcid":false,"given":"Uri","family":"Abadi","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Department of Hematology Meir Medical Center  Kfar Saba Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah\u2010Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Gafter\u2010Gvili","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah\u2010Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Department of Medicine A Rabin Medical Center, Beilinson Campus  Petah\u2010Tikva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1838-5466","authenticated-orcid":false,"given":"Ronit","family":"Gurion","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center  Petah\u2010Tikva Israel"},{"name":"Gray Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"e_1_2_12_2_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: B\u2010Cell Lymphomas. Version 2023","author":"National Comprehensive Cancer Network","year":"2023"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03918-6"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26737"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn478"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05306-2"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2008.03.002"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2417"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0287"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101044"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06803-0"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08428.x"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2350"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.8061"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1110748"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04155-2"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2828"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/157290"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70136","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:04:32Z","timestamp":1777982672000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/ejh.70136"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70136","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"2025-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}